Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| EVAX | 6-K | bullish | 7/10 | Evaxion announced it will present three-year clinical efficacy data for its personalized cancer vaccine EVX-01 at the ES | Jul 17, 2026 |
| LSTA | 8-K | neutral | 3/10 | Lisata Therapeutics (LSTA) and Kuva Labs extended the Outside Date of their existing Merger Agreement from July 17, 2026 | Jul 17, 2026 |
| FBLG | EFFECT | bearish | 6/10 | The SEC declared effective FibroBiologics' S-1 registration statement (File No. 333-297353) on July 16, 2026, enabling t | Jul 17, 2026 |
| NBP | 6-K | neutral | 3/10 | NovaBridge Biosciences adopted a new 2026 Omnibus Share Incentive Plan, authorizing up to 11,960,000 ordinary shares (5, | Jul 17, 2026 |
| SNY | 6-K | bullish | 6/10 | Sanofi announced FDA approval of subcutaneous Sarclisa Escena (isatuximab-irfc) for all existing multiple myeloma indica | Jul 17, 2026 |
| EVAX | PRESS-RELEASE | neutral | 4/10 | Evaxion will present three-year Phase 2 data for personalized cancer vaccine EVX-01 at ESMO 2026 (Oct 23-27). The third- | Jul 17, 2026 |
| GSK | 6-K | neutral | 1/10 | GSK announced the re-appointment of Deloitte LLP as its external auditor effective from the financial year ending Decemb | Jul 17, 2026 |
| KLRS | 8-K | bullish | 7/10 | Kalaris Therapeutics reported positive expanded Phase 1a SAD data for TH103 in nAMD, showing a mean 9.2-letter BCVA gain | Jul 17, 2026 |
| RGNX | PRESS-RELEASE | bearish | 7/10 | REGENXBIO priced a $100M underwritten public offering of 10M shares at $9.00/share plus 1.1M pre-funded warrants, repres | Jul 17, 2026 |
| GSK | 6-K | bearish | 5/10 | GSK announced that its Phase III CALM-1 trial for camlipixant in refractory chronic cough met its primary endpoint (50mg | Jul 17, 2026 |
| KLRS | PRESS-RELEASE | bullish | 6/10 | Kalaris Therapeutics reported positive additional Phase 1a SAD data for TH103 in neovascular AMD, showing improved durab | Jul 17, 2026 |
| CPRX | EFFECT | bearish | 5/10 | Catalyst Pharmaceuticals received SEC effectiveness on July 16, 2026 for four separate shelf registration statements (Fi | Jul 17, 2026 |
| JSPR | 8-K | mixed | 7/10 | Jasper Therapeutics entered into a definitive merger agreement to acquire Kira Pharmaceuticals, with Kira shareholders r | Jul 17, 2026 |
| ISPC | S-1/A | bearish | 7/10 | iSpecimen filed Amendment No. 2 to its S-1 registration statement, increasing the maximum offering from $4M to $5M (up t | Jul 17, 2026 |
| ANL | 6-K | bullish | 5/10 | Adlai Nortye announced the first patient dosed in the intermittent weekly (QW) dosing arm of the global Phase 1 trial fo | Jul 17, 2026 |
| CRDF | CLUSTER | mixed | 6/10 | Two insiders (CEO and a Director) purchased a total of ~$1.05M in CRDF shares at $1.455/share on July 14, two days befor | Jul 17, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | Insider selling by CEO Martine Rothblatt and EVP/General Counsel Paul Mahon totaling $8.2M, but representing only 0.036% | Jul 17, 2026 |
| PTCT | CLUSTER | neutral | 3/10 | Three PTC Therapeutics insiders, including the CFO and Chief Technical Ops Officer, sold a total of $1.40M in stock over | Jul 17, 2026 |
| ABT | COURT-RULING | neutral | 3/10 | A federal magistrate judge has recommended dismissing with prejudice a qui tam False Claims Act lawsuit against Abbott L | Jul 16, 2026 |
| STLN | CLUSTER | neutral | 3/10 | A small insider cluster at Oncology Institute (TOI) shows a 10% owner buying $88K in shares while the CMO sold $116K aft | Jul 16, 2026 |
| GILD | CLUSTER | neutral | 2/10 | Two GILD C-suite executives (CFO and Chief Communications Officer) each sold 3,000 shares in open-market transactions on | Jul 16, 2026 |
| ZVSA | 8-K | bearish | 5/10 | ZyVersa Therapeutics (ZVSA) downlisted from the OTCQB Venture Market to the OTC Pink Limited Market effective July 16, 2 | Jul 16, 2026 |
| CORT | COURT-RULING | bullish | 4/10 | Corcept won a limited discovery ruling in its antitrust defense against Teva Pharmaceuticals. The court granted Corcept | Jul 16, 2026 |
| TEVA | COURT-RULING | neutral | 2/10 | A federal magistrate judge partially granted and partially denied Corcept Therapeutics' motion to compel discovery from | Jul 16, 2026 |
| JSPR | PRESS-RELEASE | mixed | 8/10 | Jasper Therapeutics acquired Kira Pharmaceuticals in an all-stock transaction, concurrent with a $132M private placement | Jul 16, 2026 |
| HELP | 6-K | bearish | 5/10 | Cybin Inc. (HELP) filed a material change report confirming the pricing and closing of a $50M underwritten offering of 1 | Jul 16, 2026 |
| CMND | 6-K | neutral | 3/10 | Clearmind Medicine announced positive ex vivo mucoadhesion results for its intranasal formulation of MEAI, demonstrating | Jul 16, 2026 |
| BPTH | 8-K | bearish | 7/10 | Bio-Path Holdings is executing a radical pivot from a cash-strapped biotech to a crypto-focused digital asset treasury c | Jul 16, 2026 |
| ARTL | DEFA14A | neutral | 5/10 | No summary provided | Jul 16, 2026 |
| ESPR | EFFECT | bearish | 5/10 | Esperion Therapeutics received SEC effectiveness on two shelf registration statements (File Nos. 333-201198 and 333-1971 | Jul 16, 2026 |